Oppenheimer maintained its Outperform rating on Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares and lifted the price target ...

The upcoming Conversations in Dermatology 2025 event will discuss best practices for the treatment of chronic spontaneous urticaria, prurigo nodularis, and psoriasis.

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

The upcoming Conversations in Dermatology 2025 event will discuss best practices for the treatment of chronic spontaneous urticaria, prurigo nodularis, and psoriasis. During the Conversations in ...

为解决Prurigo Nodularis（PN）患者疾病负担评估不足及非生物制剂治疗满意度不明确的问题，研究人员开展了一项横断面调查PN TREK。研究通过132例美国PN患者的PROMs（患者报告结局指标）分析发现，WI-NRS≥7患者存在更严重的皮肤疼痛、睡眠障碍及生活质量（QoL ...

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced mixed results from two late-stage studies, AERIFY-1 and ...

Fintel reports that on May 28, 2025, HC Wainwright & Co. initiated coverage of Trevi Therapeutics (NasdaqGM:TRVI) with a Buy ...

chronic obstructive pulmonary disease (COPD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), bullous pemphigoid (BP), and chronic ...

Along with vitiligo, povorcitinib is also in phase 3 testing for hidradenitis suppurativa, and phase 2 for prurigo nodularis, chronic spontaneous urticaria, and asthma.

KT-621, the first STAT6 directed medicine to enter clinical evaluation, has the opportunity to transform treatment paradigms for more than 130 million patients around the world, including children and ...